Prelude Therapeutics Incorporated
PRLDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Prelude Therapeutics Incorporated focuses on Biotechnology services and products. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. The $423.0M market capitalization puts PRLD squarely in small-cap range for its industry. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Market Cap
$423.0M
Beta
0.96
P/E (TTM)
—
P/E (Fwd)
-7.07
EPS (TTM)
$-0.73
EPS (Fwd)
$-0.75
ROE
-57.7%
ROA
-27.2%
Cash
$151.8M
Total Debt
$17.6M
Free CF
-$13.8M
52W Change
358.8%
Annual Financials
Cash vs Debt
Where PRLD stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PRLD finished 32.12% above its 150-day moving average ($4.11) and 51.68% above its 200-day moving average ($3.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRLD overbought or oversold?
At the September 3, 2026 close, PRLD's RSI(14) was 51.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $151.8M in cash and $17.6M in debt, PRLD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$13.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -57.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Prelude Therapeutics Incorporated's trajectory.